Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
Public ClinicalTrials.gov record NCT04323046. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study identification
- NCT ID
- NCT04323046
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 9 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Quality-of-Life Assessment Other
- Questionnaire Administration Other
Biological · Other
Eligibility (public fields only)
- Age range
- 6 Months to 25 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2020
- Primary completion
- Jun 29, 2028
- Completion
- Jun 29, 2028
- Last update posted
- Jun 14, 2026
2020 – 2028
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham, Children's of Alabama | Birmingham | Alabama | 35233 | — |
| Children's Hospital of Los Angeles | Los Angeles | California | 90027 | — |
| Rady Children's Hospital | San Diego | California | 92123 | — |
| University of California, San Francisco | San Francisco | California | 94115 | — |
| Children's National Hospital | Washington D.C. | District of Columbia | 20310 | — |
| University of Florida | Gainesville | Florida | 32611 | — |
| Riley Children's Hospital | Indianapolis | Indiana | 46202 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Washington University St. Louis | St Louis | Missouri | 63110 | — |
| Hackensack Meridian Children's Health at Joseph M. Sanzari Children's Hospital | Hackensack | New Jersey | 07601 | — |
| Duke Children's Hospital & Health Center | Durham | North Carolina | 27705 | — |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| University of Utah | Salt Lake City | Utah | 84113 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04323046, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04323046 live on ClinicalTrials.gov.